Drug Guidance
Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy
Condition
Cardiovascular
Neurology
6 February 2026
-
Published on 06 Feb 2026
Last Updated on 06 Feb 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended eplontersen or vutrisiran for inclusion on the MOH List of Subsidised Drugs for treating stage 1 or 2 hereditary transthyretin amyloidosis with polyneuropathy. The decision was based on unfavourable cost effectiveness at the prices proposed by the companies.